🔥🐔 BizChicken 🐔🔥
Learn About the Corporations Around You
Sign Up Today!
Sign up for BizChicken and discover more about the corporations around you.
Stoke Therapeutics, Inc.
Market Cap: Medium
Employees: Low
STK-001, STK-002
Stoke Therapeutics, Inc. is an early-stage biopharmaceutical company focused on developing antisense oligonucleotide medicines to treat genetic diseases. Their lead product, STK-001, is aimed at treating Dravet syndrome, while STK-002 targets autosomal dominant optic atrophy.
Symbol: STOK
Recent Price: $10.80
Industry: Biotechnology
CEO: Dr. Edward M. Kaye M.D., Ph.D.
Sector: Healthcare
Employees: 110
Address: 45 Wiggins Avenue, Bedford, MA 01730
Phone: 781 430 8200
Leadership
- Edward M. Kaye, M.D., Chief Executive Officer & Director
- Jonathan Allan, J.D., General Counsel
- Isabel Aznarez, Ph.D., Senior Vice President, Discovery Research and Co-Founder
- Jason Hoitt, Chief Commercial Officer
- Dawn Kalmar, Chief Communications Officer
- Tommy Leggett, Chief Financial Officer
- Shamim Ruff, Chief Regulatory Officer
- Barry S. Ticho, M.D., Ph.D., FACC, Chief Medical Officer
- Joan Wood, Chief Human Resources Officer
- Adrian Krainer, Ph.D., Co-founder & Director
- Arthur Tzianabos, Ph.D., Chairman
- Jennifer Burstein, MBA, CPA, Director
- Seth L. Harrison, M.D., Director
- Arthur Levin, Ph.D., Director
- Garry E. Menzel, Ph.D., MBA, Director
- Ian F. Smith, Director
- Julie Anne Smith, Director
Last updated: 2024-12-31